Member Policies - Medical Policies - Alabama
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Hemophilia Drug Management
- Medical Policies
- PET, MRI, MRA, CT, CTA/CCTA
- Provider-Administered Drug Policies (Excluding Oncology)
- Provider-Administered Oncology Drug Policies
- Radiation Therapy Management (RTM)
- Self-Administered Drug Policies
- Transgender Services
Draft Provider-Administered Oncology Policies - Blue Advantage
Policies Currently on Draft:
- Abraxane® (paclitaxel, protein-bound)
- Alimta® (pemetrexed disodium)
- Erbitux® (cetuximab)
- Kymriah™ (tisagenlecleucel)
- Vectibix® (panitumumab)
- Yescarta (axicabtagene ciloleucel)
To ensure that the development of Blue Advantage oncology policies occurs through an open, collaborative process, we welcome physicians and other providers to submit comments about pharmacy policies that are in the draft stage. We accept comments for 45 days from the posting date listed on the draft policy. Our current draft policies are listed below.
Note: Coverage is subject to member's specific benefits. Group specific policies will supersede these policies when applicable. Please refer to member's benefit plan.
How to Submit Comments
Participating providers can submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to draft policies using one of the following methods:
Comment on Draft Medical Policy
Send comments by mail or fax to:
Blue Cross and BlueShield of Alabama
Attn: Health Management - Medical Policy
P.O. Box 995
Birmingham, AL 35298-0001
Fax: 205-220-0878